Ranbaxy has received an Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its New-Jersey based Ohm Laboratories. An EIR signifies that all issues and concerns of non-compliance observed by the FDA in its December audits have been rectified satisfactorily.
Ohm Labs is currently the only facility certified for this purpose as Ranbaxy’s other units at Paonta Sahib, Dewas and Mohali (all in India) have been barred following deviations from compliance norms.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.15 |
| Dr. Reddys Lab | 1292.20 |
| Cipla | 1311.05 |
| Zydus Lifesciences | 955.65 |
| Lupin | 2278.85 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: